Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

This publication has 23 references indexed in Scilit:

• Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2018
• Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
  Annals of Oncology, 2018
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
  Science, 2018
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
  Science, 2018
• Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
  Lung Cancer, 2017
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
  New England Journal of Medicine, 2016
• An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
  Cancer Chemotherapy and Pharmacology, 2014
• Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
  Bone Marrow Transplantation, 2012
• Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer
  Journal of Infection and Chemotherapy, 2009
• Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
  New England Journal of Medicine, 2008